FAM168A (family with sequence similarity 168 member A), also known as tongue cancer resistance-associated protein 1 (TCRP1), is a protein involved in cancer cell survival and proliferation through multiple signaling pathways. Primary Function: FAM168A acts as a linker protein that directly binds to BCR-ABL1 and AKT1, mediating downstream signaling cascades 1. It protects cancer cells from DNA damage and apoptosis, at least partly through the PI3K/AKT/NFKB signaling pathway and by stabilizing POLB protein levels through reduced ubiquitination. Mechanism: FAM168A regulates AKT1 phosphorylation and nuclear NFκB translocation, affecting cell cycle progression at the G2/M checkpoint 1. The gene is also a target of EBV-miR-BART1-3p, which suppresses FAM168A expression and impairs gastric cancer cell proliferation and invasion 2. Disease Relevance: FAM168A expression is significantly elevated in chr11 myeloid leukemia (CML) patients compared to healthy controls, and its knockdown prolongs survival in mouse xenograft models 1. Clinical Significance: FAM168A and its homolog FAM168B are emerging as potential targets for chimeric antigen receptor (CAR) T cell-based cancer immunotherapy due to their membrane-associated expression on cancer cells 3, suggesting therapeutic potential in treating multiple cancer types.